KEAP1 mutations render therapy and/or stress resistance in lung cancer and the above-mentioned differential cisplatin response was a direct reflection of their NRF2-KEAP1 status (Kansanen et al., 2013). This evidence concerns the gene NFE2L2 and lung cancer.